arrow
D

Diana Mandelker

Memorial Sloan Kettering Cancer Center
H指数:46
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Subclinical Telomere Biology Disorder in Cancer Patients Heterozygous for the RTEL1 R1264H Founder Variant

癌症患者中杂合子RTEL1 R1264H始祖变异的亚临床端粒生物学障碍

2025-12-010
PRE
Paired tumor-normal sequencing provides insights into the CDKN2A-associated tumor spectrum

配对肿瘤-正常测序为CDKN2A相关肿瘤谱提供了见解

2025-11-190
OAAI
Prospective characterization of germline variants in patients with gliomas and glioneuronal tumors

胶质瘤和神经胶质神经元肿瘤患者胚系变异的前瞻性表征

2025-09-120
OAAI
Germline landscape of high grade serous ovarian cancer across age groups: Is age just a number?

高级别浆液性卵巢癌在年龄组间的种系景观:年龄仅仅是一个数字吗?

2025-08-130
PRE
Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy

种系遗传变异影响克隆造血景观和发展为恶性肿瘤

2025-07-150
OAAI
Detection and Characterization of RB1 Mosaicism in Patients With Retinoblastoma Receiving cfDNA Test

视网膜母细胞瘤患者接受cfDNA检测中的RB1嵌合现象的检测与特征分析

2025-05-081
PRE
PROSPECTIVE GERMLINE SEQUENCING OF PATIENTS WITH GLIOMAS, GLIONEURONAL OR NEURONAL TUMORS
2024-11-110
PRE
A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms
2024-08-060
PRE
Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations
2024-07-231
PRE
Novel Mechanisms of CDH1 Inactivation in Breast Invasive Lobular Carcinoma Unveiled by the Integration of Artificial Intelligence and Genomics
2024-05-020
PRE
Universal germline genetic testing in patients with hematologic malignancies using DNA isolated from nail clippings

使用从指甲剪下的DNA对血液系统恶性肿瘤患者进行通用种系基因检测

2024-04-042
OAAI
Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization
2024-02-013
PRE
Pathogenic germline variants in patients with endometrial cancer of diverse ancestry
CANCER
IF5.1
2023-10-276
PRE